Oncogene Oncogene aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research. Oncogene propagates work that challenges standard conjecture and builds on previous studies, in particular those that lead to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers, and in processes that drive metastatic spread, and provide important insights into cancer biology beyond what has been revealed thus far. Areas covered by Oncogene include, but are not limited to, the cellular and molecular biology of cancer including resistance to cancer therapies, and development of better approaches to improving survival. Across cancer biology, we have a broad remit encompassing the life sciences and biomedicine, from the most fundamental and theoretical work, through to translational, applied, and clinical research. http://feeds.nature.com/onc/rss/current Nature Publishing Group en © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Oncogene © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. [email protected]
  • Oncogene https://www.nature.com/uploads/product/onc/rss.gif http://feeds.nature.com/onc/rss/current <![CDATA[Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling]]> https://www.nature.com/articles/s41388-025-03601-y <![CDATA[
    See More

    Oncogene, Published online: 24 October 2025; doi:10.1038/s41388-025-03601-y

    Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling]]> <![CDATA[Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling]]> Mingrong ZuoShuxin ZhangSiliang ChenYuze HeJunhong LiYufan XiangYunbo YuanTengfei LiWanchun YangZhihao WangWenhao LiNi ChenYuan YangYunhui ZengQing MaoMina ChenYanhui Liu doi:10.1038/s41388-025-03601-y Oncogene, Published online: 2025-10-24; | doi:10.1038/s41388-025-03601-y 2025-10-24 Oncogene 10.1038/s41388-025-03601-y https://www.nature.com/articles/s41388-025-03601-y <![CDATA[Super-enhancer-associated long noncoding RNA lnc-SPI1U mediates SPI1 feedback regulation by interacting with HNRNPH1 and HNRNPF]]> https://www.nature.com/articles/s41388-025-03612-9 <![CDATA[

    Oncogene, Published online: 24 October 2025; doi:10.1038/s41388-025-03612-9

    Super-enhancer-associated long noncoding RNA lnc-SPI1U mediates SPI1 feedback regulation by interacting with HNRNPH1 and HNRNPF]]>     <![CDATA[Super-enhancer-associated long noncoding RNA lnc-SPI1U mediates SPI1 feedback regulation by interacting with HNRNPH1 and HNRNPF]]> Xuefei MaYilu LiWeifen SunJiacheng LouYi ZhangYun TanXuefeng WangKankan Wang doi:10.1038/s41388-025-03612-9 Oncogene, Published online: 2025-10-24; | doi:10.1038/s41388-025-03612-9 2025-10-24 Oncogene 10.1038/s41388-025-03612-9 https://www.nature.com/articles/s41388-025-03612-9     <![CDATA[DARPP-32 is a novel regulator of M2-macrophage polarization: Sustains STAT6 phosphorylation by directly binding and inhibiting tyrosine phosphatase SHP-1]]> https://www.nature.com/articles/s41388-025-03610-x <![CDATA[

    Oncogene, Published online: 24 October 2025; doi:10.1038/s41388-025-03610-x

    DARPP-32 is a novel regulator of M2-macrophage polarization: Sustains STAT6 phosphorylation by directly binding and inhibiting tyrosine phosphatase SHP-1]]>     <![CDATA[DARPP-32 is a novel regulator of M2-macrophage polarization: Sustains STAT6 phosphorylation by directly binding and inhibiting tyrosine phosphatase SHP-1]]> Sangita ChowdhuryArppita SethiSwati SrivastavaVishal UpadhyayShivkant MishraAgniv ShomeAnil Kumar SinghShyam SinghMadan Lal Brahma BhattAnand MishraArun Kumar Trivedi doi:10.1038/s41388-025-03610-x Oncogene, Published online: 2025-10-24; | doi:10.1038/s41388-025-03610-x 2025-10-24 Oncogene 10.1038/s41388-025-03610-x https://www.nature.com/articles/s41388-025-03610-x     <![CDATA[HRH1-targeting mAb: a precision therapeutic strategy for Glioblastoma]]> https://www.nature.com/articles/s41388-025-03613-8 <![CDATA[

    Oncogene, Published online: 23 October 2025; doi:10.1038/s41388-025-03613-8

    HRH1-targeting mAb: a precision therapeutic strategy for Glioblastoma]]>     <![CDATA[HRH1-targeting mAb: a precision therapeutic strategy for Glioblastoma]]> Kankai WangPeiqi ZhaoXiaohong ZhuFan TangHong ChenYing ZhangHao WangYu ChenYuanbo PanQichuan ZhugeJianjing Yang doi:10.1038/s41388-025-03613-8 Oncogene, Published online: 2025-10-23; | doi:10.1038/s41388-025-03613-8 2025-10-23 Oncogene 10.1038/s41388-025-03613-8 https://www.nature.com/articles/s41388-025-03613-8     <![CDATA[High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma: spatial context reshapes the gene expression landscape]]> https://www.nature.com/articles/s41388-025-03608-5 <![CDATA[

    Oncogene, Published online: 23 October 2025; doi:10.1038/s41388-025-03608-5

    High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma: spatial context reshapes the gene expression landscape]]>     <![CDATA[High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma: spatial context reshapes the gene expression landscape]]> Kuan Cheok LeiNalini SrinivasMitalee ChandraVahan SerobyanSelma UgurelDaniel HoffmannThibault KervarrecWeng-Onn LuiJürgen C. Becker doi:10.1038/s41388-025-03608-5 Oncogene, Published online: 2025-10-23; | doi:10.1038/s41388-025-03608-5 2025-10-23 Oncogene 10.1038/s41388-025-03608-5 https://www.nature.com/articles/s41388-025-03608-5     <![CDATA[High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-κB1 pathway in epithelial ovarian cancer]]> https://www.nature.com/articles/s41388-025-03609-4 <![CDATA[

    Oncogene, Published online: 22 October 2025; doi:10.1038/s41388-025-03609-4

    High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-κB1 pathway in epithelial ovarian cancer]]>     <![CDATA[High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-κB1 pathway in epithelial ovarian cancer]]> Song TangKelie ChenFang ZhengZhiqin FuYuequn NiuXinxin LiuHeng NiXiaoyu YuanZhenyan CuiWeiguo LuDajing XiaYihua Wu doi:10.1038/s41388-025-03609-4 Oncogene, Published online: 2025-10-22; | doi:10.1038/s41388-025-03609-4 2025-10-22 Oncogene 10.1038/s41388-025-03609-4 https://www.nature.com/articles/s41388-025-03609-4     <![CDATA[On-genetic inactivation of caspase-3 and P53 increases cancer cell fitness by PDIA4 redistribution]]> https://www.nature.com/articles/s41388-025-03606-7 <![CDATA[

    Oncogene, Published online: 21 October 2025; doi:10.1038/s41388-025-03606-7

    On-genetic inactivation of caspase-3 and P53 increases cancer cell fitness by PDIA4 redistribution]]>     <![CDATA[On-genetic inactivation of caspase-3 and P53 increases cancer cell fitness by PDIA4 redistribution]]> Gal TwitoFaiza Amterat Abu AbayedAyelet GiladSuma BiadsyNoa GavrielSuad Sheikh SulimanYarden MizrahiHila MeggedMor TenenboimNaim Abu-FrehaAeid Igbaria doi:10.1038/s41388-025-03606-7 Oncogene, Published online: 2025-10-21; | doi:10.1038/s41388-025-03606-7 2025-10-21 Oncogene 10.1038/s41388-025-03606-7 https://www.nature.com/articles/s41388-025-03606-7     <![CDATA[Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma]]> https://www.nature.com/articles/s41388-025-03605-8 <![CDATA[

    Oncogene, Published online: 21 October 2025; doi:10.1038/s41388-025-03605-8

    Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma]]>     <![CDATA[Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma]]> Nobutoshi EsakiTomoka SakodaRyota AndoYuki MiyaiTadashi IidaYasuyuki MizutaniMirai YoshidaYuki HaraMakoto MatsuyamaTomoe KobayashiYukihiro ShirakiShinji MiiJiro IchikawaTomonori KawasakiShino ManabeTomohisa SakaiYoshihiro NishidaMasahide TakahashiAtsushi Enomoto doi:10.1038/s41388-025-03605-8 Oncogene, Published online: 2025-10-21; | doi:10.1038/s41388-025-03605-8 2025-10-21 Oncogene 10.1038/s41388-025-03605-8 https://www.nature.com/articles/s41388-025-03605-8